TY - JOUR
T1 - Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer’s disease
AU - Chen, Yijun
AU - Zeng, Xuemei
AU - Olvera-Rojas, Marcos
AU - Sewell, Kelsey R.
AU - Sehrawat, Anuradha
AU - Gu, Jeremy
AU - Triviño-Ibañez, Eva María
AU - Solis-Urra, Patricio
AU - Gómez- Río, Manuel
AU - Oberlin, Lauren E.
AU - Kramer, Arthur F.
AU - Hillman, Charles H.
AU - Burns, Jeffrey M.
AU - Marsland, Anna L.
AU - Kang, Chaeryon
AU - McAuley, Edward
AU - Ikonomovic, Milos D.
AU - Pascoal, Tharick A.
AU - Villemagne, Victor L.
AU - Lopez, Oscar L.
AU - Cohen, Ann D.
AU - Esteban-Cornejo, Irene
AU - Yates, Nathan A.
AU - Erickson, Kirk I.
AU - Karikari, Thomas K.
N1 - This study was supported by the Joseph A. Massaro Alzheimer’s Research Fund of The Pittsburgh Foundation (AD2018-97918), the National Institutes of Health (P30 AG066468, P01 AG025204, and R01 AG083874). The AGUEDA study was supported by grants RTI2018-095284-J-I00, PID2022-137399OB-I00 and CNS2024-154835 funded by MCIN/AEI/10.13039/501100011033/ and “ERDF A way of making Europe”. The IGNITE study was funded by the National Institutes of Health (R01 AG053952) awarded to K.I.E., J.M.B., A.F.K., E.M. and R35 AG072307 awarded to KIE. Use of REDcap for the project was sponsored by the Clinical and Translational Science Institute at the University of Pittsburgh (UL1-TR-001857) and the University of Kansas Medical Center (P30 AG072973; UL1 TR002366). TKK and members of the Karikari Laboratory were further supported by NIH/NIA (R01 AG083874, U24AG082930, P30 AG066468, RF1AG077474, R01 AG083156, R37 AG023651, R01 AG025516, R01 AG073267, R01 AG075336, R01 AG072641, P01 AG025204), NIH/NINDS (U01 NS131740, U01 NS141777), NIH/NIMH (R01 MH108509), Aging Mind Foundation (DAF2255207), DoD (HT94252320064), the Anbridge Charitable Fund, and a professorial endowment from the Department of Psychiatry, University of Pittsburgh. MOR was supported by the Spanish Ministry of Science, Innovation and Universities (FPU 22/02476). PSU was supported by MICIU/AEI /10.13039/501100011033 and FEDER, UE (PID2022-137399OB-I00). IEC was supported by a grant RYC2019-027287-I funded by MCIN/AEI/10.13039/501100011033/ and “ESF Investing in your future”. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The authors are thankful to the participants in the IGNITE, AGUEDA and ADRC cohorts whose dedication and commitment were fundamental to the successful implementation of this study. An earlier version of this work was included in the doctoral dissertation of Yijun Chen, “Innovative Pre-Analytical Strategies and Method Development for Blood-Based Biomarkers of Alzheimer’s Disease” (University of Pittsburgh, 2025) in ProQuest. The current manuscript represents a revised and extended version of that work.
PY - 2026
Y1 - 2026
N2 - Plasma amyloid-β (Aβ) peptides, alone or in ratio with p-tau217, show strong potential as Alzheimer’s disease biomarkers. While immunoprecipitation-mass spectrometry (IP-MS) is the preferred method for plasma Aβ quantification, current assays are resource- and time-intensive. Here, we developed a streamlined IP-MS method using a cost-effective instrument that significantly improved the efficiency of an original assay by incorporating a single immunoprecipitation step, an optimized buffer system, and approximately 75% reductions in antibody and sample volume requirements. Technical validation revealed excellent dilution linearity (r²>0.99), high precision (< 10% variation), enhanced sensitivity, improved Aβ recovery, and markedly increased signal-to-noise ratios. In a large cohort of cognitively normal older adults (n = 317), the plasma Aβ1-42/Aβ1-40 ratio achieved stronger concordance with Aβ-PET and superior accuracies to identify abnormal scans (AUC 0.81 vs. 0.65 for the original assay). Notably, accuracies remained high even with plasma volumes as low as 100 μL. The improved IP-MS method enables robust and simplified plasma Aβ assessment in Alzheimer’s disease, with implications for prognosis, diagnosis and intervention trials.
AB - Plasma amyloid-β (Aβ) peptides, alone or in ratio with p-tau217, show strong potential as Alzheimer’s disease biomarkers. While immunoprecipitation-mass spectrometry (IP-MS) is the preferred method for plasma Aβ quantification, current assays are resource- and time-intensive. Here, we developed a streamlined IP-MS method using a cost-effective instrument that significantly improved the efficiency of an original assay by incorporating a single immunoprecipitation step, an optimized buffer system, and approximately 75% reductions in antibody and sample volume requirements. Technical validation revealed excellent dilution linearity (r²>0.99), high precision (< 10% variation), enhanced sensitivity, improved Aβ recovery, and markedly increased signal-to-noise ratios. In a large cohort of cognitively normal older adults (n = 317), the plasma Aβ1-42/Aβ1-40 ratio achieved stronger concordance with Aβ-PET and superior accuracies to identify abnormal scans (AUC 0.81 vs. 0.65 for the original assay). Notably, accuracies remained high even with plasma volumes as low as 100 μL. The improved IP-MS method enables robust and simplified plasma Aβ assessment in Alzheimer’s disease, with implications for prognosis, diagnosis and intervention trials.
UR - https://www.scopus.com/pages/publications/105030200953
UR - https://www.scopus.com/pages/publications/105030200953#tab=citedBy
U2 - 10.1038/s41467-026-68372-w
DO - 10.1038/s41467-026-68372-w
M3 - Article
C2 - 41571708
AN - SCOPUS:105030200953
SN - 2041-1723
VL - 17
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 1673
ER -